Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Rheumatology Women's Health Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Clinical Trial Active — Not Recruiting NCT03270982

Comprehensive Segmental Revision System

Comprehensive Segmental Revision System — Active Not Recruiting • Oncology • NCT03270982.

📅 09 Jun 2026 ⏱ 1 min read
Active — Not Recruiting
Check the registry for current status and eligibility criteria.
Status
Active — Not Recruiting
NCT ID
NCT03270982
Start
2016-04
Completion
2035-12
ClinicaliQ Trial Snapshot
  • Comprehensive Segmental Revision System — Active Not Recruiting • Oncology • NCT03270982.
  • A study evaluating how well the Comprehensive Segmental Revision System works for complex spinal reconstruction surgery.

Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.

Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

Clinical Data evaluation to document the performance and clinical outcomes of the Comprehensive Segmental Revision System. Conditions: Degenerative Disease, Oncology, Revision Surgery, Trauma, Rheumatoid Arthritis Interventions: Comprehensive SRS Replacement Lead Sponsor: Zimmer Biomet Planned Enrollment: 105 participants

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Clinical Brief
‘My cancer spread while I waited months for surgery’: The cost of England’s cancer wait times
Oncology · BBC Health · 10 Sep 2026
England's cancer surgery waiting times have deteriorated despite government initiatives aimed at improving them, with patients experiencing significant delays that may allow…
View brief →
Clinical Brief
Lucy Davis urges women to check their breasts for cancer – here’s how
Oncology · BBC Health · 12 Aug 2026
Breast cancer can present as subtle findings—a hard spot rather than a discrete lump—emphasising the importance of thorough self-examination and patient awareness…
View brief →
Guideline
Lisocabtagene maraleucel for treating relapsed or refractory follicular lymphoma after 2 or more lines of systemic treatment (terminated evaluation)
Oncology · 20 Aug 2026
This NICE evaluation was terminated, meaning lisocabtagene maraleucel is not currently recommended for routine NHS use in relapsed or refractory follicular lymphoma—do…
View guideline →
Guideline
Tisotumab vedotin for treating recurrent or metastatic cervical cancer that has progressed on or after systemic treatment
Oncology · 11 Jun 2026
Tisotumab vedotin is recommended for cervical cancer patients with recurrent or metastatic disease that has progressed despite prior systemic treatment—consider this as…
View guideline →
Guideline
Durvalumab with platinum-based chemotherapy, then with or without olaparib, for untreated advanced or recurrent endometrial cancer
Oncology · 09 Sep 2026
Durvalumab combined with platinum-based chemotherapy is the recommended first-line treatment for untreated advanced or recurrent endometrial cancer, with olaparib addition considered based…
View guideline →
Guideline
Pembrolizumab with chemoradiotherapy for untreated locally advanced cervical cancer
Oncology · 14 Jul 2026
Pembrolizumab combined with chemoradiotherapy is recommended for untreated locally advanced cervical cancer, improving survival outcomes compared to chemoradiotherapy alone—consider this combination as…
View guideline →